Potential role of Hsp90 inhibitors in overcoming cisplatin resistance of bladder cancer-initiating cells

For metastatic bladder cancer patients, systemic cisplatin (CDDP)-based combination chemotherapy is the first-line choice of treatment. Although up to 70% of advanced bladder cancer patients initially show good tumor response to this form of combination chemotherapy, over 90% of good responders rela...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Int J Cancer
Päätekijät: Tatokoro, Manabu, Koga, Fumitaka, Yoshida, Soichiro, Kawakami, Satoru, Fujii, Yasuhisa, Neckers, Len, Kihara, Kazunori
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7447157/
https://ncbi.nlm.nih.gov/pubmed/21964864
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ijc.26475
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia